Published in Cardiovascular Business Week, May 2nd, 2006
Chemokine Therapeutics achieved a number of important milestones in its first year operating as a public company including:
Release of results of phase I clinical trials for the company's immune booster drug CTCE-0214 in healthy volunteers: the company confirmed that the safety profile and efficacy results from the phase I trial of CTCE-0214 warrant continued development;
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cardiovascular Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.